EVERSANA

    Company Information

    EVERSANA was founded on January 2018. The company is based in Milwaukee, WI, USA . The number of employees in EVERSANA is less than 5000. Eversana is the provider of global services to the life science industry.

    Here is how EVERSANA describes itself: "The life sciences sector is changing by the minute. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. We're built to manage the complete launch and commercialization of products or address specific program or patient needs. We are EVERSANA."
      If you are the founder or part of the founding team, please tell the world your story




        EVERSANA has not received any venture funding.

          Similar Companies [beta]

            Venture Categories

              Active Venture Investors




                Venture Competitors

                  News

                      EVERSANA - Blog

                        • News Alert: 4th Draft of Northern Ireland Protocol Focuses on “Uninterrupted Security of Supply of Medicines”

                        • PRICENTRIC BRIEF The European Commission has proposed a number of amendments to the Northern Ireland protocol draft, focused on ensuring “uninterrupted security of supply of medicines” from Great Britain to Northern Ireland The proposal stipulates that companies in the UK would “keep all their regulatory functions where they are currently located” when supplying the Northern Irish […]The post News Alert: 4th Draft of Northern Ireland Protocol Focuses on “Uninterrupted Security of Supply of Medicines” first appeared on EVERSANA.
                        • EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization

                        • CHICAGO and KANSAS CITY, Mo. — October 20, 2021 — EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, and Intouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreement to incorporate Intouch’s industry-leading creative and media services, enterprise solutions and data […]The post EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization first appeared on EVERSANA.
                        • Global Pricing Insights – Last Week In Review – Oct 11 – 15, 2021

                        • PRICENTRIC BRIEF The French Government has unveiled the social security financing bill (PLFSS) for 2022, containing plans regarding expenditure linked to COVID-19, a continuation of the Ségur de la santé and the forecast of a social deficit of more than EUR 21 billion; presented to the Council of Ministers on October 7, 2021, the PLFSS […]The post Global Pricing Insights – Last Week In Review – Oct 11 – 15, 2021 first appeared on EVERSANA.
                        • EVERSANA Acquires Protean; strengthens operational strategy and excellence in market access, channel and patient services

                        • CHICAGO— October 15, 2021 — EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, today announced the acquisition of Protean, the leading market access consulting firm, specializing in channel and trade, patient services and payer contracting operations. The acquisition immediately strengthens EVERSANA’s integrated services designed to help companies commercialize or overcome […]The post EVERSANA Acquires Protean; strengthens operational strategy and excellence in market access, channel and patient services first appeared on EVERSANA.
                        • News Alert: ICER Reviews MyoKardia & Bristol-Myers Squibb’s Mavacamten in HCM

                        • PRICENTRIC BRIEF: In its newly published Evidence Report, the Institute for Clinical and Economic Review (ICER) said MyoKardia and Bristol-Myers Squibb’s mavacamten may offer important health benefits in the treatment of hypertrophic cardiomyopathy (HCM) David Rind, MD, ICER’s Chief Medical Officer, stated, “The evidence suggests that mavacamten may deliver important health benefits for patients with […]The post News Alert: ICER Reviews MyoKardia & Bristol-Myers Squibb’s Mavacamten in HCM first appeared on EVERSANA.
                        • MINDPAX and EVERSANA announce U.S. commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders

                        • CHICAGO — October 12, 2021 — The leadership team at MINDPAX Inc., the leading digital therapeutic company focused on bipolar disorders, today announces its partnership with EVERSANA™ to launch and commercialize its therapeutics in the United States. MINDPAX combines remote clinical assessment and targeted digital therapy to improve patients’ clinical conditions. The solution provides personalized […]The post MINDPAX and EVERSANA announce U.S. commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders first appeared on EVERSANA.

                        Share:     facebook    twitter    linkedin    reddit    email

                          Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                          Leave a Reply

                          Your email address will not be published. Required fields are marked *